FDA Approves Aptivus for HIV Infection

Aptivus (tipranavir) is a non-peptidic protease inhibitor that works by inhibiting protease, an enzyme needed to complete the HIV replication process. Aptivus, co-administered with 200 mg of ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.

Posted: June 2005

Related Articles:

Aptivus (tipranavir) FDA Approval History

View comments

Hide
(web2)